AAIC 2026 reported that an Alzheimer's blood test substantially improved diagnostic accuracy among primary-care clinicians in an interim Swedish study. Adults with new memory symptoms should view this as promising evidence—not as support for self-testing or an instant, stand-alone diagnosis. A blood-biomarker test measures substances associated with Alzheimer's disease in a blood sample. It can help clinicians judge whether Alzheimer's-related brain changes are present, but it does not establish what alone is causing someone's symptoms.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the primary-care study find?
- What does the test actually show?
- Why isn't this a stand-alone diagnosis?
- What should you do about new memory symptoms?
What did the primary-care study find?
The study included 1,310 people with mild cognitive impairment or dementia and 165 physicians. Of those patients, 383 received primary care and 927 received specialist care. For the primary-care patients, clinicians recorded a diagnosis before and after receiving results from PrecivityAD2.
Their accuracy rose from 65% to 93%. Dementia specialists evaluating the same patients reached 94% accuracy. Researchers compared those decisions with cerebrospinal fluid testing, amyloid PET imaging, and expert consensus. According to the Alzheimer's Association report on the interim study, primary-care clinicians changed 30% of their diagnoses after seeing the blood-test results.
What does the test actually show?
precivityad2 measures blood amyloid beta and phosphorylated tau. These biomarkers are linked to Alzheimer's pathology—the biological changes associated with the disease. That information can strengthen or weaken the case for Alzheimer's, but it cannot prove that Alzheimer's alone caused a person's memory problems.
Someone may have Alzheimer's-related biomarkers alongside another condition that affects thinking. Negative results were especially useful in the study. After receiving them, primary-care clinicians' willingness to rule out Alzheimer's rose from 12.9% to 25%, prompting greater attention to other possible causes.
Why isn't this a stand-alone diagnosis?
The findings come from an interim real-world study in Sweden. Clinicians remained cautious about positive results and often wanted confirmation from a specialist. Commercial blood tests also differ in accuracy.
The Alzheimer's Association's 2025 clinical guidance says these tests should follow a comprehensive clinical evaluation and be interpreted within that broader context. Those recommendations specifically covered people with objective cognitive impairment receiving specialized memory care. In the United States, the first FDA-cleared Alzheimer's blood test is the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio. The FDA's clearance notice limits its intended use to symptomatic adults age 55 or older in specialized care; it is neither a screening test nor a stand-alone diagnostic test.
What should you do about new memory symptoms?
Arrange a clinical evaluation rather than starting with a blood-test request. Describe what has changed, when it began, how often it happens, and whether it interferes with work, appointments, medication use, finances, driving, or other daily tasks.
Before the visit: Memory symptoms do not always mean Alzheimer's disease. The National Institute on Aging identifies other possible causes, including depression, medication effects, sleep problems, vitamin deficiencies, and thyroid, kidney, or liver problems.
- Write down specific examples of memory or thinking problems.
- List prescription drugs, over-the-counter medicines, and supplements.
- Note changes in mood, sleep, or general health.
- Ask whether a family member should attend and share observations.
- Ask what the test results would change about diagnosis or follow-up care.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Adults With New Memory Symptoms Should Know About the News
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Adults With New Memory Symptoms Should Know About the News
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Adults With New Memory Symptoms Should Know About the News
